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Anti-topoisomerase I antibodies; Immunofluorescence pattern 24 2 Systemic sclerosis (SSc) is a chronic autoimmune disease characterised by skin and internal 25 organs fibrosis, vascular damage and positive antinuclear autoantibodies (ANAs). The 26 classical antigenic specificities of ANAs are anti-centromere (ACA), anti-topoisomerase I 27 antibodies (anti-topo I) and the more recently described anti-RNA polymerase III antibodies 28 (anti-RNAPIII). 29
Anti-RNAPIII, firstly described in SSc in 1993 [1] , are currently admitted as specific SSc-30 related autoantibodies and have been incorporated into the 2013 ACR/EULAR classification 31 criteria for the disease [2] . The prevalence of anti-RNAPIII partially depends on the 32 geographic origin of patients [3] . In France, the prevalence is low and ranges from 3 to 9% 33 whereas it can reach 14% in North America and 41% in South America [3, 4] . The ANA 34 pattern associated with anti-RNAPIII was described as a fine-speckled nuclear stain with 35 additional occasional bright dots, with or without concurrent punctate nucleolar staining but 36 no typical pattern was proposed [5] . Anti-RNAPIII are mainly associated with a diffuse 37 cutaneous subtype, scleroderma renal crisis and a risk of cancer in close temporal relationship 38 to SSc onset [3, 4, 6, 7] . As the specific method for their identification was the 39 radioimmunoprecipitation assay, a cumbersome method not suitable for routine practice, these 40 autoantibodies were not routinely looked for. More recently immunoenzymatic methods have 41 been developed, but, the detection strategy was not clearly established for routine practice [5] . 42
Although the positivity of ACA and anti-topo I is considered to be exclusive, the co-positivity 43 of anti-RNAPIII with these SSc-specific auto-antibodies remains to be clarified. In order to 44 design the best strategy for anti-RNAPIII detection, we aimed to 1/ evaluate the co-positivity 45 SSc patients (<10 AU/ml). Results were expressed as median +/-interquartile range or as 60 frequencies (fq). Medians were compared using Mann Whitney U Test. Frequencies were 61 compared using Chi 2 Test. 62
Among the 76 selected sera of SSc patients, 33 patients (43%) were positive for ACA and 43 63 (57%) for anti-topo I antibodies. Immunofluorescence nuclear patterns were: centromeric 64 (n=32), nucleolar homogeneous (n=41), speckled-centromeric (n=1), speckled-homogeneous 65 (n=1) and mixed speckled-nucleolar-centromeric (n=1). Anti-RNAPIII were investigated in 66 these SSc patients: only one ACA-positive serum (1.3%) was found also positive for anti-67 RNAPIII with a titer of 192 AU/ml. This serum corresponded to the mixed speckled-68 nucleolar-centromeric immunofluorescence nuclear pattern (Figure 1) . No other specificities 69 associated with a speckled pattern (anti-Ro/SSA anti-La/SSB, anti-Sm, anti-RNP) were 70 detected. The patient, a 47-year-old female, had a diffuse cutaneous subset, with digital 71 ulcers, joint contractures, a reduced diffuse lung capacity for carbon monoxide and 72 oesophageal reflux disorder. Her medical history was remarkable for an ovarian4 adenocarcinoma that was diagnosed 6 years before SSc, and considered in remission after 74 surgery and radio-chemotherapy. 75
Then, we retrospectively analysed immunofluorescence pattern and clinical characteristics of 76 8 SSc patients found positive for anti-RNAPIII in our laboratory. The various 77 immunofluorescence aspects were nuclear speckled (n=5), nucleolar (n=1), nucleolar-78 speckled (n=1) (Figure 2 ) and mixed speckled-nucleolar-centromeric (n=1) (Figure 1) . The 79 median titer of anti-RNAPIII was 54 [18-298] AU/ml. 80 Table 1 
